TABLE OF CONTENTS
1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.3 OVERVIEW OF GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET 40
1.4 CURRENCY AND PRICING 42
1.5 LIMITATIONS 42
1.6 MARKETS COVERED 42
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 DBMR TRIPOD DATA VALIDATION MODEL 49
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
2.6 MULTIVARIATE MODELLING 53
2.7 PRODUCTS LIFELINE CURVE 53
2.8 DBMR MARKET POSITION GRID 54
2.9 SECONDARY SOURCES 56
2.10 ASSUMPTIONS 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 60
4.1 CLINICAL TRIALS 63
4.2 RECENT DEVELOPMENTS 63
4.3 BRAND COMPETITIVE ANALYSIS 63
4.4 SUPPLY CHAIN ANALYSIS 64
5 MARKET OVERVIEW 65
5.1 DRIVERS 67
5.1.1 RISING INCIDENCES OF INBORN ERRORS OF METABOLISM 67
5.1.2 PREFERENCE OF DIETARY SUPPLEMENTS OVER ENZYME REPLACEMENT THERAPY 67
5.1.3 GOVERNMENT INITIATIVES AND PROGRAMS FOR CREATING AWARENESS ABOUT IEM 68
5.1.4 INCREASE IN THE NUMBER OF NEW BORN SCREENING PROCEDURES 68
5.2 RESTRAINTS 69
5.2.1 INADEQUATE REIMBURSEMENT SCENARIO 69
5.2.2 STRINGENT REGULATIONS FOR MEDICAL FOODS 69
5.2.3 HIGH COST OF MEDICAL FOODS 70
?
5.3 OPPORTUNITIES 71
5.3.1 INNOVATIVE PRODUCT LAUNCHES FOR NEW INDICATIONS 71
5.3.2 INCREASING SPENDING ON MEDICAL FOODS PRODUCTS 71
5.4 CHALLENGES 73
5.4.1 PRODUCT RECALLS 73
5.4.2 POOR ACCESSIBILITY OF MEDICAL FOODS 73
6 COVID-19 IMPACT ANALYSIS 74
7 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS 75
7.1 OVERVIEW 76
7.2 AMINO ACID 77
7.2.1 SINGLE AMINO ACID 78
7.2.1.1 L-ARGININE 79
7.2.1.2 L-ISOLEUCINE 79
7.2.1.3 L-TYROSINE 79
7.2.1.4 L-LEUCINE 79
7.2.1.5 GLYCINE 79
7.2.1.6 OTHERS 79
7.2.2 AMINO ACID MIXTURES 80
7.2.2.1 PHENYLADE 80
7.2.2.1.1 DRINK MIX 81
7.2.2.1.2 GMP MIX-IN 81
7.2.2.1.3 GMP READY 81
7.2.2.1.4 OTHERS 81
7.2.2.2 PERIFLEX 81
7.2.2.3 LOPHLEX 81
7.2.2.4 PHLEXY 81
7.2.2.5 COOLER 81
7.2.2.6 ANAMIX 81
7.2.2.7 LYSINE-FREE, LOW TRYPTOPHAN 82
7.2.2.8 GLUTARADE ESSENTIAL GA-1 82
7.2.2.9 GLUTARADE GA-1 AMINO ACID BLEND 82
7.2.2.10 GLYTACTIN WITH GMP 82
7.2.2.11 OTHERS 82
7.3 LOW PROTEIN FOOD 82
7.4 GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON 83
7.5 LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON 84
7.6 OTHERS 85
8 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP 86
8.1 OVERVIEW 87
8.2 INFANTS 88
8.3 WEANING 88
8.4 ADOLESCENT 89
8.5 ADULTS 90
9 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES 91
9.1 OVERVIEW 92
9.2 PHENYLKETONURIA (PKU) 93
9.2.1 PHENYLADE 94
9.2.2 PERIFLEX 94
9.2.3 LOPHLEX 94
9.2.4 OTHERS 94
9.3 TYROSINEMIA TYPES I AND II 95
9.4 MAPLE SYRUP URINE DISEASE (MSUD) 95
9.4.1 ANAMIX 96
9.4.2 COOLER 97
9.4.3 MSUD GEL 97
9.4.4 AMINO ACID BLEND 97
9.4.5 MAXMUM 97
9.4.6 OTHERS 97
9.5 HOMOCYSTINURIA 97
9.6 GLUTARIC ACIDEMIA TYPE I 98
9.7 UREA CYCLE DISORDERS 99
9.8 METHYLMALONIC ACIDEMIA 99
9.9 ISOVALERIC ACIDEMIA 100
9.10 ORGANIC ACIDURIAS 101
9.11 RENAL DISEASE 102
9.12 PROPIONIC ACIDEMIA 102
9.13 DISORDERS OF LEUCINE METABOLISM 103
9.14 OTHERS 104
?
10 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORM 105
10.1 OVERVIEW 106
10.2 POWDER 107
10.3 LIQUID 107
10.4 OTHERS 108
11 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING 109
11.1 OVERVIEW 110
11.2 CAN 111
11.3 PACKET 111
11.4 BOTTLE 112
11.5 JAR 113
11.6 OTHERS 114
12 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL 115
12.1 OVERVIEW 116
12.2 RETAIL PHARMACIES 117
12.3 HOSPITAL PHARMACIES 117
12.4 DRUGS STORES 118
12.5 ONLINE PHARMACIES 119
12.6 OTHERS 119
13 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION 121
13.1 OVERVIEW 122
13.2 NORTH AMERICA 127
13.2.1 U.S. 135
13.2.2 CANADA 140
13.2.3 MEXICO 145
13.3 EUROPE 150
13.3.1 GERMANY 158
13.3.2 FRANCE 163
13.3.3 U.K. 168
13.3.4 ITALY 173
13.3.5 SPAIN 178
13.3.6 SWITZERLAND 183
13.3.7 NETHERLANDS 188
13.3.8 BELGIUM 193
13.3.9 DENMARK 198
13.3.10 RUSSIA 203
13.3.11 SWEDEN 208
13.3.12 TURKEY 213
13.3.13 POLAND 218
13.3.14 REST OF EUROPE 223
13.4 ASIA-PACIFIC 224
13.4.1 CHINA 232
13.4.2 JAPAN 237
13.4.3 INDIA 242
13.4.4 AUSTRALIA 247
13.4.5 SOUTH KOREA 252
13.4.6 THAILAND 257
13.4.7 SINGAPORE 262
13.4.8 INDONESIA 267
13.4.9 MALAYSIA 272
13.4.10 NEW ZEALAND 277
13.4.11 VIETNAM 282
13.4.12 PHILIPPINES 287
13.4.13 REST OF ASIA-PACIFIC 292
13.5 SOUTH AMERICA 293
13.5.1 BRAZIL 301
13.5.2 ARGENTINA 306
13.5.3 REST OF SOUTH AMERICA 311
13.6 MIDDLE EAST & AFRICA 312
13.6.1 SOUTH AFRICA 320
13.6.2 SAUDI ARABIA 325
13.6.3 OMAN 330
13.6.4 REST OF MIDDLE EAST & AFRICA 335
14 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, COMPANY LANDSCAPE 336
14.1 COMPANY SHARE ANALYSIS: GLOBAL 336
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 337
14.3 COMPANY SHARE ANALYSIS: EUROPE 338
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 339
?
15 COMPANY PROFILE 340
15.1 ABBOTT 340
15.1.1 COMPANY SNAPSHOT 340
15.1.2 REVENUE ANALYSIS 341
15.1.3 COMPANY SHARE ANALYSIS 341
15.1.4 PRODUCT PORTFOLIO 342
15.1.5 RECENT DEVELOPMENT 342
15.2 BIOMARIN 343
15.2.1 COMPANY SNAPSHOT 343
15.2.2 REVENUE ANALYSIS 343
15.2.3 COMPANY SHARE ANALYSIS 344
15.2.4 PRODUCT PORTFOLIO 344
15.2.5 RECENT DEVELOPMENT 344
15.3 MEAD JOHNSON & COMPANY, LLC. (A SUBSIDIARY OF RECKITT BENCKISER GROUP PLC.) 345
15.3.1 COMPANY SNAPSHOT 345
15.3.2 REVENUE ANALYSIS 346
15.3.3 COMPANY SHARE ANALYSIS 346
15.3.4 PRODUCT PORTFOLIO 347
15.3.5 RECENT DEVELOPMENT 347
15.4 NESTLe HEALTH SCIENCE (A SUBSIDIARY OF NESTLe) 348
15.4.1 COMPANY SNAPSHOT 348
15.4.2 REVENUE ANALYSIS 348
15.4.3 COMPANY SHARE ANALYSIS 349
15.4.4 PRODUCT PORTFOLIO 349
15.4.5 RECENT DEVELOPMENT 350
15.5 AJINOMOTO CAMBROOKE, INC. (A SUBSIDIARY OF AJINOMOTO CO., INC.) 351
15.5.1 COMPANY SNAPSHOT 351
15.5.2 REVENUE ANALYSIS 351
15.5.3 PRODUCT PORTFOLIO 352
15.5.4 RECENT DEVELOPMENTS 353
15.6 APR 354
15.6.1 COMPANY SNAPSHOT 354
15.6.2 PRODUCT PORTFOLIO 354
15.6.3 RECENT DEVELOPMENT 354
15.7 DR. SCHaR AG / SPA 355
15.7.1 COMPANY SNAPSHOT 355
15.7.2 PRODUCT PORTFOLIO 355
15.7.3 RECENT DEVELOPMENT 356
?
15.8 ENER-G FOODS, INC. 357
15.8.1 COMPANY SNAPSHOT 357
15.8.2 PRODUCT PORTFOLIO 357
15.8.3 RECENT DEVELOPMENT 357
15.9 NUTRICIA (A SUBSIDIARY OF DANONE) 358
15.9.1 COMPANY SNAPSHOT 358
15.9.2 REVENUE ANALYSIS 358
15.9.3 PRODUCT PORTFOLIO 359
15.9.4 RECENT DEVELOPMENT 361
15.10 PKU-MDMIL 362
15.10.1 COMPANY SNAPSHOT 362
15.10.2 PRODUCT PORTFOLIO 362
15.10.3 RECENT DEVELOPMENT 362
15.11 POA PHARMA 363
15.11.1 COMPANY SNAPSHOT 363
15.11.2 PRODUCT PORTFOLIO 363
15.11.3 RECENT DEVELOPMENTS 363
15.12 PRISTINE ORGANICS PRIVATE LIMITED 364
15.12.1 COMPANY SNAPSHOT 364
15.12.2 PRODUCT PORTFOLIO 364
15.12.3 RECENT DEVELOPMENT 365
15.13 PROMIN METABOLICS 366
15.13.1 COMPANY SNAPSHOT 366
15.13.2 PRODUCT PORTFOLIO 366
15.13.3 RECENT DEVELOPMENT 366
15.14 SOLACE NUTRITION 367
15.14.1 COMPANY SNAPSHOT 367
15.14.2 PRODUCT PORTFOLIO 367
15.14.3 RECENT DEVELOPMENT 367
16 SWOT & DATA BRIDGE MARKET RESEARCH ANALYSIS 368
16.1 SWOT ANALYSIS 368
16.1.1 STRENGTH: - STRONG PRODUCT PORTFOLIO 368
16.1.2 WEAKNESS: - NO INITIATIVES FOR EXPANSION 368
16.1.3 OPPORTUNITY: - INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT 368
16.1.4 THREAT: - STIFF COMPETITION 369
16.2 DATA BRIDGE MARKET RESEARCH ANALYSIS 369
?
17 CONCLUSION 370
18 QUESTIONNAIRE 371
19 RELATED REPORTS 374